The American Lawyer selected CVS Health’s $70 billion acquisition of Aetna, in which Shearman & Sterling acted as legal advisor to CVS Health, as the M&A Deal of the Year. It also named the firm to its A-List, identifying the firm as one of the top-20 law firms in the United States.
Drawing on our vast deal and case experience, Shearman & Sterling has developed this Resources page, which provides a wide array of substantive and practical information on our antitrust and competition practice. Please review some of the informative materials we regularly publish as a value-added service to our clients, as well as information on upcoming events and details of recent activities and newsworthy items.
Shearman & Sterling advised Continental AG (Continental) on the acquisition of Kathrein Automotive GmbH (Kathrein Automotive), one of the leading specialists in and manufacturers of vehicle antennas. The transaction is subject to the approval of the competition authorities and expected to close in the first quarter of 2019.
Shearman & Sterling, together with the UK State Aid Law Association, are organizing an evening seminar titled “Introducing the UK’s Independent State Aid Regime” on December 10, 2018 at The Brewery in London.
Partners Elvira Aliende Rodriguez and Geert Goeteyn (both Brussels-Antitrust) will speak at the Advanced EU Competition Law Brussels conference organized by Knect365 in Brussels on November 20 and 21, 2018.
Partner Geert Goeteyn (Brussels/London-Antitrust) will speak on “Cartel Enforcement : It’s a Global Game” at the Seventh Annual International Arbitration, Regulatory & Competition Law Summit organized by Kluwer Law in Seoul on October 24, 2018.
A senior executive of a public company has agreed to pay $609,810 in civil penalties for acquiring additional voting securities in the company without first making a Hart-Scott-Rodino Act filing and observing the statutory waiting period.
Associate Timothy Slattery (Antitrust-Washington, DC) has contributed to the Pharmaceutical Industry Antitrust Handbook (2nd Ed.) published by the American Bar Association.
Senior associate Timothy Slattery (Washington, D.C.-Antitrust) has authored the article “Sample Shaming: FDA’s Open Letter on Access to Samples Under REMS Programs Publically Calls Out Branded Drug Manufacturers to Aid Generic Entry” in Antitrust Advisors, a publication of the American Health Lawyers Association Antitrust Practice Group. The article was published in September 2018.